Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK American Depositary Shares), an increase in the notional allocation of ADSs occurred on July 20, 2012, at a price of $46.26 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: July 20, 2012 (Notification date: July 23, 2012).
- Instrument: GlaxoSmithKline American Depositary Shares (ADSs).
- Price: $46.26 per ADS.
- Parties Involved: Dr. M M Slaoui (Director) and Dr. K Slaoui (Connected Person).
- Details: Dr. K Slaoui received a notional allocation increase of 4 ADSs; Dr. M M Slaoui had no change in allocation.